Abituzumab for the treatment of colorectal cancer

US12171829B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Giorgio Massimini · Darmstadt, DE
• Ilhan Celik · Zwingenberg, DE
• Josef Straub · Seeheim-Jugenheim, DE
• Rolf Bruns · Westerstede, DE
• Rita Laeufle · San Diego, US

Key dates

• Filing date: Oct 18, 2019
• Grant date: Dec 24, 2024
• Expiry date: Dec 5, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.